Activation of the innate immune system in patients with primary hyperaldosteronism

Completed

• Conditions: bloedvataandoeningen, arteriosclerose; Conn's syndrome; primary hyperaldosteronism; 10057166

• Registration Number: NL-OMON43020
• Lead Sponsor: Radboud Universitair Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 30

Inclusion Criteria

Patients with PA (primary hyperaldosteronism):
- Diagnosis of PA according to current guideline
- Age >=18 yrs
- Written informed consent;Patients with essential hypertension:
- Exclusion of PA according to current guidelines
- Age >=18 yrs
- Written informed consent

Exclusion Criteria

- Treatment with MR antagonists within the 4 weeks before participation
- Smoking
- Diabetes mellitus
- Previous cardiovascular events (stroke, TIA, myocardial infarction)
- Heart failure
- Auto-inflammatory or auto-immune diseases
- Use of immunomodulating drugs
- Renal failure (MDRD <45)
- BMI >35
- Previous vaccination within 3 months prior to study entry.
- Current infection or clinically significant infections within 3 months before participation (defined as fever >38.5).

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primary study parameter/endpoint: Vascular wall inflammation in the aorta, the<br /><br>left and right carotid artery and the left and right iliac and femoral<br /><br>arteries, as detected with FDG-PET scanning, according to current European<br /><br>guidelines.<br /><br></p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary study parameters/endpoints:<br /><br>The inflammatory/atherogenic phenotype of circulating monocytes in PA<br /><br>patients.<br /><br>FDG uptake in spleen and bone marrow.</p><br>